In this third episode of Denatured’s series on AI in drug discovery, we discuss patient behavior and its influence on clinical trials and AI models with guests from GSK, IQVIA, Exelixis and DataHow.
Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI models? And how do providers continue to work with patients to optimize and grow data pools?
This is the third and final part of a discussion focused upon data bias, accuracy, access and the future of AI in drug development.
Guests
Paul Agapow, Director of Innovation, Data Science and Strategy, GlaxoSmithKline
Mike King, Senior Director of Product and Strategy, IQVIA
Nindhana Paranthaman, Executive Medical Director, Exelixis
Moritz von Stosch, Chief Information Officer, DataHow
Host
Lori Ellis, Head of Insights, BioSpace
Lori Ellis is the head of insights at BioSpace, providing industry analysis as well as custom content for BioSpace clients. Her current focus is on the ever-evolving impact of technology on the pharmaceutical industry. You can reach her at lori.ellis@biospace.com. Follow her on LinkedIn.
